101 Views

VC-backed Rhythm files for IPO

Rhythm has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. Citigroup and Cowen and Company are serving as the lead underwriters. Based in Boston, Rhythm is a biopharmaceutical firm that focuses on treating metabolic disorders. Its backers include MPM Capital, New Enterprise Associates, Third Rock Ventures, Ipsen and Pfizer Ventures.

VC-backed Jounce Therapeutics names new CEO

Jounce Therapeutics, which is backed by Third Rock Ventures, has hired Dr. Richard Murray as CEO. Murray is replacing interim CEO Dr. Cary Pfeffer, a partner at Third Rock Ventures, who will become chairman of Jounce’s board of directors. Previously, Murray worked at Merck where he recently served as senior vice president of biologics and vaccines research and was a member of the Merck Research Laboratories leadership team. Based in Cambridge, Mass., Jounce Therapeutics is focused on discovering and developing cancer immunotherapies.

DC Devices picks up $34 mln Series D

DC Devices, a medical device firm focused on treating heart failure, has secured $34 million in Series D funding. Accelmed led the round with participation from investors that included Third Rock Ventures, General Catalyst Partners and Lumira Capital.

VC-backed Editas Medicine hires CEO

Editas Medicine has hired Katrine S. Bosley as CEO. Previously, Bosley worked at Avila Therapeutics where she served as CEO. Based in Cambridge, Mass., Editas Medicine is a transformative genome editing firm. It is backed by Flagship Ventures, Polaris Partners, Third Rock Ventures and Partners Innovation Fund.

VC-backed Solstice Biologics hires new president/CEO and CFO

San Diego-based biotech startup Solstice Biologics, which is backed by venBio and Aeris Capital, has hired Dr. Lou Tartaglia as president and CEO. Tartaglia has also been added to the firm’s board of directors. Also, the firm has named John Borgeson as chief financial officer. Previously, Tartaglia worked at Third Rock Ventures where he was a partner while Borgeson was vice president of finance for Pfizer‘s biotherapeutic and bioinnovation center.

108 Views

Nurix launches with Series B

Third Rock Ventures and The Column Group have backed the launch of Nurix with a $25.1 million Series B financing. Nurix develops therapies that modulate the ubiquitin proteasome system.

Kala Pharmaceuticals scores $22.5 mln

Kala Pharmaceuticals said Wednesday that it has closed $22.5 million in Series B financing. Ysios Capital led the round with participation from Crown Venture Fund, Lux Capital, Polaris Partners and Third Rock Ventures. In addition to the funding, Dr. Karen Wagner, a general partner at Ysios Capital, has been added to Kala’s board of directors. Based in Waltham, Mass., Kala Pharmaceuticals is a developer of treatments for ocular diseases.

PanOptica snags $45 mln Series B funds

PanOptica said Tuesday that it has closed up to $45 million in Series B funding. Novo Ventures and Third Rock Ventures led the round with participation from SV Life Sciences. Headquartered in Bernardsville, NJ, PanOptica is a biopharmaceutical firm focused on ophthalmology therapies.

SAGE Therapeutics nabs $38 mln Series C funds

SAGE Therapeutics has closed $38 million in Series C financing. Investors included OrbiMed Advisors, EcoR1 Capital Management, Foresite Capital Management, Third Rock Ventures and ARCH Venture Partners. Based in Cambridge, Mass., SAGE Therapeutics is a biopharmaceutical company focused on treating orphan central nervous system disorders.

SAGE Therapeutics secures $20m Series B financing

Biopharmaceutical company SAGE Therapeutics has secured a $20 million Series B financing from investors ARCH Venture Partners and Third Rock Ventures, bringing the total raised to $57.8 million since launch in 2011. The Series B financing will accelerate clinical and preclinical efforts to continue to advance SAGE’s pipeline programs in CNS disorders.

Taris Biomedical Raises $12.5 Million

Taris Biomedical, a specialty pharmaceutical company developing therapies to treat bladder diseases, has raised a fresh $12.5 million in funding from its existing investors, Flagship Ventures, Flybridge Capital Partners, Polaris Partners, and Third Rock Ventures. With the new funding, Taris, based in Lexington, Mass., has raised $49.8 million altogether.

Cibiem Appoints President and CEO

Medical device company Cibiem has appointed Ken Martin to president and chief executive officer. Martin will succeed Cibiem co-founder Howard R. Levin who will continue his active involvement within the company and as a member of its board of directors.The company is backed by SV Life Sciences and Third Rock Ventures.

Kala Pharmaceuticals Secures $11.5m Series A

Kala Pharmaceuticals has secured $11.5 million in Series A equity financing through new and existing investors. New and lead investor Crown Venture Fund the venture capital arm of the Crown family of Chicago, joined Kala’s existing investors including Lux Capital Management, Polaris Venture Partners and Third Rock Ventures.

Shire Acquires Lotus Tissue Repair

Shire has signed an agreement to acquire Lotus Tissue Repair. The business is a private biotechnology company launched in 2011 by a team of biotechnology entrepreneurs and life sciences investor, Third Rock Ventures.

PEHUB Community

Join the 12503 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

PE HUB News Briefs

RSS Feed Widget

Marketplace

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget